The bordetella pertussis type III secretion system tip complex protein Bsp22 is not a protective antigen and fails to elicit serum antibody responses during infection of humans and mice

Infection and Immunity

Volumn 81, Issue 8, 2013, Pages 2761-2767

  Villarino Romero, Rodrigo ^a   Bibova, Ilona ^a   Cerny, Ondrej ^a   Vecerek, Branislav ^a   Wald, Tomas ^a   Benada, Oldrich ^a   Zavadilova, Jana ^b   Osicka, Radim ^a   Seboa, Peter ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL VACCINE; RECOMBINANT BSP22; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD SAMPLING; BORDETELLA BRONCHISEPTICA; BORDETELLA PERTUSSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LUNG INFECTION; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROVOCATION TEST; TYPE III SECRETION SYSTEM;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORDETELLA INFECTIONS; BORDETELLA PERTUSSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED BALB C; WHOOPING COUGH;

EID: 84880648112     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00353-13     Document Type: Article

References (40)

1. Cotter PA, Miller JF. 2000. Genetic analysis of the Bordetella infectious cycle. Immunopharmacology 48:253-255.
2. Mattoo S, Cherry JD. 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18:326-382.
3. Crowcroft NS, Stein C, Duclos P, Birmingham M. 2003. How best to estimate the global burden of pertussis? Lancet Infect. Dis. 3:413-418.
4. Cherry JD. 2010. The present and future control of pertussis. Clin. Infect. Dis. 51:663-667.
5. Andrews R, Herceg A, Roberts C. 1997. Pertussis notifications in Australia, 1991 to 1997. Commun. Dis. Intell. 21:145-148.
6. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. 2000. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg. Infect. Dis. 6:348-357.
7. Gzyl A, Augustynowicz E, van Loo I, Slusarczyk J. 2001. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 20:299-303.
8. He Q, Makinen J, Berbers G, Mooi FR, Viljanen MK, Arvilommi H, Mertsola J. 2003. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of anti-genic variants? J. Infect. Dis. 187:1200-1205.
9. Hellenbrand W, Beier D, Jensen E, Littmann M, Meyer C, Oppermann H, Wirsing von Konig CH, Reiter S. 2009. The epidemiology of pertussis in Germany: past and present. BMC Infect. Dis. 9:22. doi: 10.1186/1471-2334-9-22.
10. King AJ, Berbers G, van Oirschot HE, Hoogerhout P, Knipping K, Mooi FR. 2001. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147:2885-2895.
11. Raguckas SE, VandenBussche HL, Jacobs C, Klepser ME. 2007. Pertussis resurgence: diagnosis, treatment, prevention, and beyond. Pharmacotherapy 27:41-52.
12. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. 2003. Trends in pertussis among infants in the United States, 1980-1999. JAMA 290:2968-2975.
13. Witt MA, Katz PH, Witt DJ. 2012. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin. Infect. Dis. 54:1730-1735.
14. Clark TA, Messonnier NE, Hadler SC. 2012. Pertussis control: time for something new? Trends Microbiol. 20:211-213.
15. Poolman JT, Hallander H, Halperin SA. 2012. Pertussis vaccines: where to now? Expert Rev. Vaccines 10:1497-1500.
16. Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, Mooi FR, Boyd A, Mills KH. 2008. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect. Immun. 76:1257-1266.
17. Coburn B, Sekirov I, Finlay BB. 2007. Type III secretion systems and disease. Clin. Microbiol. Rev. 20:535-549.
18. Galan JE, Wolf-Watz H. 2006. Protein delivery into eukaryotic cells by type III secretion machines. Nature 444:567-573.
19. Ghosh P. 2004. Process of protein transport by the type III secretion system. Microbiol. Mol. Biol. Rev. 68:771-795.
20. Shrivastava R, Miller JF. 2009. Virulence factor secretion and transloca-tion by Bordetella species. Curr. Opin. Microbiol. 12:88-93.
21. Kozak NA, Mattoo S, Foreman-Wykert AK, Whitelegge JP, Miller JF. 2005. Interactions between partner switcher orthologs BtrW and BtrV regulate type III secretion in Bordetella. J. Bacteriol. 187:5665-5676.
22. Mattoo S, Yuk MH, Huang LL, Miller JF. 2004. Regulation of type III secretion in Bordetella. Mol. Microbiol. 52:1201-1214.
23. Yuk MH, Harvill ET, Cotter PA, Miller JF. 2000. Modulation of host immune responses, induction of apoptosis and inhibition of NF-KB activation by the Bordetella type III secretion system. Mol. Microbiol. 35:991-1004.
24. Yuk MH, Harvill ET, Miller JF. 1998. The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol. Microbiol. 28:945-959.
25. Han HJ, Kuwae A, Abe A, Arakawa Y, Kamachi K. 2011. Differential expression of type III effector BteA protein due to IS481 insertion in Bordetella pertussis. PLoS One 6:e17797. doi: 10.1371/journal.pone.0017797.
26. Gaillard ME, Bottero D, Castuma CE, Basile LA, Hozbor D. 2011. Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality. Infect. Immun. 79:3677-3682.
27. Skinner JA, Reissinger A, Shen H, Yuk MH. 2004. Bordetella type III secretion and adenylate cyclase toxin synergize to drive dendritic cells into a semimature state. J. Immunol. 173:1934-1940.
28. Medhekar B, Shrivastava R, Mattoo S, Gingery M, Miller JF. 2009. Bordetella Bsp22 forms a filamentous type III secretion system tip complex and is immunoprotective in vitro and in vivo. Mol. Microbiol. 71:492-504.
29. Antoine R, Locht C. 1990. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect. Immun. 58:1518-1526.
30. Stainer DW, Scholte MJ. 1970. A simple chemically defined medium for the production of phase I Bordetella pertussis. J. Gen. Microbiol. 63:211-220.
31. Khan F, He M, Taussig MJ. 2006. Double-hexahistidine tag with high-affinity binding for protein immobilization, purification, and detection on ni-nitrilotriacetic acid surfaces. Anal. Chem. 78:3072-3079.
32. Benada O, Pokorny V. 1990. Modification of the Polaron sputter-coater unit for glow-discharge activation of carbon support films. J. Electron Microsc. Technol. 16:235-239.
33. Ozcengiz E, Kilinc K, Buyuktanir O, Gunalp A. 2004. Rapid purification of pertussis toxin (PT) and filamentous hemagglutinin (FHA) by cation-exchange chromatography. Vaccine 22:1570-1575.
34. Karimova G, Fayolle C, Gmira S, Ullmann A, Leclerc C, Ladant D. 1998. Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells. Proc. Natl. Acad. Sci. U. S. A. 95:12532-12537.
35. + T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites. Infect. Immun. 68:247-256.
36. Guiso N, Berbers G, Fry NK, He Q, Riffelmann M, Wirsing von Konig CH. 2011. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur. J. Clin. Microbiol. Infect. Dis. 30:307-312.
37. Betsou F, Sebo P, Guiso N. 1993. CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin. Infect. Immun. 61:3583-3589.
38. Betsou F, Sebo P, Guiso N. 1995. The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin. Infect. Immun. 63:3309-3315.
39. Carbonetti NH, Artamonova GV, Andreasen C, Dudley E, Mays RM, Worthington ZE. 2004. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Infect. Immun. 72: 3350-3358.
40. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2:e65. doi:10.1371/journal.ppat.0020065.